Physician profile
Brian A Leish
NPI 1417087073
$3,306.82
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $643 · 2020: $429 · 2021: $544 · 2022: $949 · 2023: $742.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $742.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $742.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $519.00 | 2019-2023 | Farxiga |
| Janssen Pharmaceuticals, INC | $312.54 | 2019-2023 | Xarelto |
| Amgen INC. | $256.82 | 2019-2023 | Otezla, Repatha, Evenity |
| Novo Nordisk INC | $252.82 | 2019-2023 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $199.15 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $171.88 | 2019-2023 | Vaxneuvance, Gardasil 9, Verquvo |
| Abbvie INC. | $152.35 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $148.72 | 2022-2023 | |
| Astellas Pharma US INC | $128.45 | 2019-2021 | |
| Glaxosmithkline, LLC. | $103.58 | 2019-2023 | Shingrix |
| Biohaven Pharmaceutical Holding Company LTD. | $98.51 | 2022 | |
| Amarin Pharma, INC. | $98.37 | 2019-2022 | |
| Allergan, INC. | $96.70 | 2020 | |
| Boston Scientific Corporation | $89.77 | 2019-2022 | |
| Pfizer INC. | $88.60 | 2022-2023 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $61.62 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $60.35 | 2022-2023 | Jynarque |
| Almatica Pharma LLC | $49.33 | 2022-2023 | Loreev Xr |
| Exact Sciences Corporation | $47.08 | 2023 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $46.21 | 2019-2020 | |
| Eisai INC. | $44.49 | 2020-2021 | |
| Lilly USA, LLC | $41.13 | 2022-2023 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $27.22 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $26.66 | 2023 | Crysvita |
| Kyowa Kirin, INC. | $25.47 | 2023 | |
| Genentech USA, INC. | $22.46 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.85 | 2021 | |
| Bausch Health US, LLC | $18.18 | 2019 | |
| Shield Therapeutics INC | $17.42 | 2022 | |
| Qiagen, LLC | $17.36 | 2021 | |
| Ibsa Pharma INC. | $15.49 | 2022 | |
| Optos, INC. | $14.31 | 2021 | |
| Daiichi Sankyo INC. | $13.21 | 2019 | |
| Endogastric Solutions, INC | $12.30 | 2022 | |
| Itamar Medical INC | $8.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Leish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.